Spirulina for Allergic Rhinitis

Allergic Rhinitis — scientific infographic poster

Allergic rhinitis is the single clinical indication where Spirulina has the most consistent and best-controlled randomized trial evidence. The Cingi 2008 double-blind placebo-controlled trial in patients with allergic rhinitis — published in European Archives of Oto-Rhino-Laryngology — found that Spirulina significantly improved nasal discharge, sneezing, nasal congestion, and itching compared with placebo (P < 0.001). A separate 2020 randomized trial in 53 patients compared Spirulina 2 g/day with cetirizine 10 mg/day for two months and reported greater improvement in runny nose, nasal obstruction, and reduced smell in the Spirulina group. The proposed mechanism, from animal and cell studies plus one small human cytokine study, is suppression of immunoglobulin E-driven mast cell histamine release (shown in rats and mice), downregulation of IL-4 production by Th2 cells, and rebalancing of the Th1/Th2 cytokine axis; in the one human cytokine study in allergic rhinitis, IL-4 fell while the Th1 cytokines measured did not change. Spirulina is one of several natural interventions with controlled trials in allergic rhinitis (butterbur has the larger trial record), a finding most relevant to people who tolerate antihistamines poorly (sedation, anticholinergic effects, tachyphylaxis) or who prefer a non-pharmaceutical option.


Table of Contents

  1. The Cingi 2008 Reference Trial
  2. Immunoglobulin E and Mast Cell Histamine Release
  3. Th2 Cytokines and IL-4 Suppression
  4. Th1/Th2 Rebalancing
  5. Polysaccharide Effects on Immune Cells
  6. Spirulina vs Antihistamines — Head-to-Head Data
  7. Allergic Asthma Overlap
  8. Atopic Dermatitis Suggestive Evidence
  9. Doses Used in Allergic Rhinitis Research
  10. Cautions in the Research
  11. Key Research Papers
  12. Connections
  13. Featured Videos

The Cingi 2008 Reference Trial

The Cingi et al. 2008 trial, from Turkey, is the trial most often cited for Spirulina in allergic rhinitis. What its published abstract reports:

The abstract does not give the number of participants, the dose, or the trial length, and figures for these that circulate online are not confirmed by it. It remains a single trial from one centre; a 2020 trial against cetirizine (below) is the only other controlled human trial with symptom outcomes in allergic rhinitis cited on this page (the 2005 Mao crossover trial, below, measured cytokines only). A PubMed search run for this page in November 2026 found no human allergic-rhinitis trial of Spirulina published after the 2020 cetirizine comparison, so these two symptom trials are the whole clinical record so far.

Back to Table of Contents

Immunoglobulin E and Mast Cell Histamine Release

The proposed mechanism for Spirulina in allergic rhinitis starts from the pathophysiology. Allergic rhinitis is an immunoglobulin E-mediated type I hypersensitivity reaction. The cascade:

  1. An aeroallergen (pollen, dust mite, animal dander, mold spore) is presented to a naive B cell by a dendritic cell in mucosal lymphoid tissue under Th2-cytokine conditions (IL-4 in particular)
  2. The B cell undergoes class-switch recombination from immunoglobulin M (IgM) to immunoglobulin E (IgE)
  3. The allergen-specific immunoglobulin E binds to high-affinity FcepsilonRI receptors on tissue mast cells and circulating basophils, "arming" them
  4. On subsequent allergen exposure, allergen cross-links the immunoglobulin E on mast cell surfaces, triggering degranulation
  5. Mast cells release histamine, tryptase, prostaglandin D2, leukotrienes (LTC4, LTD4, LTE4), and chemokines that recruit eosinophils
  6. The cascade produces the classic allergic rhinitis symptoms: rhinorrhea (histamine on H1 receptors), congestion (vasodilation), sneezing (sensory nerve stimulation), itching (sensory nerve stimulation)

Conventional antihistamines (loratadine, fexofenadine, cetirizine, levocetirizine) block H1 receptors on tissues, preventing histamine's downstream effects. They do not prevent mast cell degranulation, so the inflammatory mediators are still released — just unable to bind H1 receptors.

Spirulina operates upstream. In vitro and in animal models, Spirulina extracts inhibit immunoglobulin E-mediated mast cell degranulation, reducing the release of histamine, tryptase, and downstream chemokines. This is mechanistically more comparable to mast-cell-stabilizer drugs (cromolyn sodium) than to antihistamines, although the effect appears to involve both surface immunoglobulin E-FcepsilonRI signaling interference and intracellular signaling pathway modulation.

Back to Table of Contents

Th2 Cytokines and IL-4 Suppression

Beyond acute mast cell stabilization, Spirulina addresses the upstream Th2 polarization that drives initial immunoglobulin E production and the ongoing allergic inflammation. The Mao et al. 2005 study was a randomized, double-blind, placebo-controlled crossover trial in people with allergic rhinitis, who took placebo or Spirulina at 1,000 mg or 2,000 mg a day for 12 weeks. At 2,000 mg/day, Spirulina reduced IL-4 production by stimulated peripheral blood mononuclear cells (PBMCs) by 32%. The Th1 cytokines it measured, interferon-gamma (IFN-gamma) and interleukin-2 (IL-2), did not change, and the trial measured cytokines only, not symptoms.

This is mechanistically important because:

Reducing IL-4 production interrupts the self-amplifying allergic inflammation loop. New immunoglobulin E production is reduced, new Th2 cells are not as readily polarized, and the existing Th2 population is not as well sustained. The clinical implication is that the symptomatic benefit of Spirulina supplementation may continue to grow over months as the underlying immunologic state shifts, not just provide acute symptom relief.

Back to Table of Contents

Th1/Th2 Rebalancing

The atopic march of childhood — eczema, food allergy, asthma, allergic rhinitis — is associated with a developmental skewing of the immune system toward Th2 polarization. The "hygiene hypothesis" framework suggests that reduced infectious-disease exposure in early childhood (cleaner water, vaccines, antibiotics) leaves the immune system inadequately educated by Th1-promoting infectious stimuli, resulting in a population-level shift toward Th2-dominated atopic disease.

The implication for therapy is that interventions that shift the Th1/Th2 balance toward Th1 may have systemic anti-atopic effects, going beyond simple symptom management. The human data on this point are limited and mixed. In 11 healthy men, a commercial spirulina polysaccharide extract raised the Th1 cytokines tumor necrosis factor-alpha (TNF-alpha), IL-2 and IFN-gamma produced in response to a test antigen after 3 days, with the rise in IL-2 still present after 56 days, and 3 days of use “inhibited the IL-4 responses”; added to blood cells in a dish, the same extract produced strong TNF-alpha, interleukin-1beta (IL-1beta) and IL-6 responses, which the authors read as “a pro-inflammatory state” (Løbner et al., 2008). In people with allergic rhinitis, by contrast, the Mao 2005 trial found that Spirulina did not change the Th1 cytokines IFN-gamma and IL-2.

In mice fed a crude shrimp extract as an allergen, Hayashi et al. (1998) found that the rise in serum immunoglobulin E (IgE) caused by the allergen “was not further enhanced” by a Spirulina extract, while immunoglobulin A (IgA) in the intestinal contents was significantly higher with Spirulina (immunoglobulin G1 also rose further). The authors concluded that Spirulina “may at least neither induce nor enhance” IgE-dependent allergic reactions such as food allergy, and may raise IgA to protect against them. These are mouse results; they do not show whether long-term Spirulina use changes the course of atopic disease in people.

The Th1/Th2 paradigm and its role in atopic and autoimmune disease are covered on the Th1/Th2 Balance page.

Back to Table of Contents

Polysaccharide Effects on Immune Cells

Two Spirulina polysaccharides are often named in this context. The first is the commercial spirulina polysaccharide extract, a high-molecular-weight polysaccharide preparation that Pugh et al. (2001) isolated and tested in the laboratory: in THP-1 human monocytes/macrophages grown in a dish, it activated the transcription factor nuclear factor kappa B (NF-kappa B) and substantially increased mRNA for IL-1beta and TNF-alpha. The second, calcium spirulan, was isolated as an antiviral compound: it inhibited the replication of several enveloped viruses, including herpes simplex virus type 1, measles, mumps, influenza A and HIV-1, by selectively blocking the entry of the virus into host cells (Hayashi T et al., 1996). Neither paper studied dendritic cells, pattern-recognition receptors, IL-12 or natural killer cells.

The only human data for the first extract come from the study of 11 healthy men described above (Løbner et al., 2008), whose authors summarised the effect as “an age-dependent, temporary enhancement of adaptive immune responses.” How these laboratory findings relate to allergic rhinitis in people has not been studied in the papers cited here.

Back to Table of Contents

Spirulina vs Antihistamines — Head-to-Head Data

Nourollahian and colleagues (2020, Iran) randomized 53 patients with allergic rhinitis to Spirulina 2 g/day or cetirizine 10 mg/day for two months. There was no placebo group and no combined-therapy group. Findings reported in the paper:

The trial was small, from one centre, and compared two active treatments without a placebo, so it cannot show how much of either effect was placebo response. Cetirizine is an established fast-acting antihistamine; the trial measured outcomes over weeks, not hours.

Back to Table of Contents

Allergic Asthma Overlap

Allergic asthma shares the immunoglobulin E-mast-cell-Th2 axis with allergic rhinitis, and the two conditions co-exist in a majority of atopic patients. The Spirulina effects on Th2 cytokine production and mast cell stabilization would, in principle, translate to benefit in allergic asthma as well.

The trial evidence in asthma specifically is much weaker than for allergic rhinitis. Small open-label and observational studies have suggested reduced inhaler use and improved asthma control questionnaire scores in patients adding Spirulina to standard asthma therapy, but the randomized controlled trials with bronchial challenge endpoints and objective spirometry have not been done.

Those small studies looked at Spirulina only as an adjunct added to standard asthma therapy. None tested it as a replacement for inhaled corticosteroids, long-acting beta-agonists, or rescue albuterol, and the research does not support substituting it for them in established asthma. The risk of an asthma exacerbation from inadequate maintenance therapy substantially exceeds any potential benefit from Spirulina.

Allergic asthma management is covered on the Allergic Asthma page.

Back to Table of Contents

Atopic Dermatitis Suggestive Evidence

Atopic dermatitis (eczema) shares the Th2 polarization and immunoglobulin E-mediated mechanisms with allergic rhinitis. Small observational studies and a few open-label trials have suggested benefit of Spirulina supplementation for atopic dermatitis severity scores, particularly in pediatric patients (under physician supervision).

Randomized controlled trials specifically in atopic dermatitis remain limited. The mechanistic case is similar to allergic rhinitis — reduce Th2 cytokine production, reduce mast cell histamine release, support Th1/Th2 rebalancing. Adults with both allergic rhinitis and atopic dermatitis taking the 2 g/day allergic rhinitis dose may see incidental skin improvement, but the evidence does not support Spirulina as the primary therapy for moderate-to-severe atopic dermatitis, where standard care uses topical corticosteroids, topical calcineurin inhibitors, or systemic immunosuppressants under dermatology guidance.

Back to Table of Contents

Doses Used in Allergic Rhinitis Research

Back to Table of Contents

Cautions in the Research

Back to Table of Contents

Key Research Papers

  1. Cingi C, Conk-Dalay M, Cakli H, Bal C (2008). The effects of Spirulina on allergic rhinitis. European Archives of Oto-Rhino-Laryngology 265(10):1219-23. — PubMed PMID: 18343939
  2. Nourollahian M, Rasoulian B, Gafari A, Anoushiravani M, Jabari F, Bakhshaee M (2020). Clinical comparison of the efficacy of spirulina platensis and cetirizine for treatment of allergic rhinitis. Acta Otorhinolaryngologica Italica 40(3):224-229 — PubMed PMID: 32773785
  3. Mao TK, Van de Water J, Gershwin ME (2005). Effects of a Spirulina-based dietary supplement on cytokine production from allergic rhinitis patients. Journal of Medicinal Food. — PubMed PMID: 15857205
  4. Mao TK, Van de Water J, Gershwin ME. Effect of Spirulina on the secretion of cytokines from peripheral blood mononuclear cells. Journal of Medicinal Food. — PubMed PMID: 19281334
  5. Hayashi O et al. Class specific influence of dietary Spirulina platensis on antibody production in mice. Journal of Nutritional Science and Vitaminology. — PubMed PMID: 10197315
  6. Yang HN et al. Spirulina platensis inhibits anaphylactic reaction. Life Sciences. — PubMed PMID: 9324065
  7. Kim HM et al. Inhibitory effect of mast cell-mediated immediate-type allergic reactions in rats by Spirulina. Biochemical Pharmacology. — PubMed PMID: 9605430
  8. Pugh N et al. Isolation of three high molecular weight polysaccharide preparations with potent immunostimulatory activity from Spirulina platensis. Planta Medica. — PubMed PMID: 11731916
  9. Løbner M et al. Enhancement of human adaptive immune responses by administration of a high-molecular-weight polysaccharide extract from the cyanobacterium Arthrospira platensis. Journal of Medicinal Food. — PubMed PMID: 18598175
  10. Nemoto-Kawamura C, Hirahashi T, Nagai T, Yamada H, Katoh T, Hayashi O (2004). Phycocyanin enhances secretary IgA antibody response and suppresses allergic IgE antibody response in mice immunized with antigen-entrapped biodegradable microparticles. Journal of Nutritional Science and Vitaminology 50(2):129-36. — PubMed PMID: 15242017
  11. Selmi C, Leung PSC, Fischer L et al. The effects of Spirulina on anemia and immune function in senior citizens. Cellular and Molecular Immunology. — PubMed PMID: 21278762
  12. Karkos PD, Leong SC, Karkos CD, Sivaji N, Assimakopoulos DA. Spirulina in clinical practice: evidence-based human applications. Evidence-Based Complementary and Alternative Medicine. — PubMed PMID: 18955364
  13. Hayashi T, Hayashi K, Maeda M, Kojima I. Calcium spirulan, an inhibitor of enveloped virus replication, from a blue-green alga Spirulina platensis. Journal of Natural Products 59(1):83-7. — PubMed PMID: 8984158

PubMed Topic Searches

  1. PubMed: Spirulina allergic rhinitis
  2. PubMed: Spirulina IgE / mast cell
  3. PubMed: Spirulina IL-4 / Th2
  4. PubMed: Spirulina polysaccharide extract
  5. PubMed: Allergic rhinitis CAM

Back to Table of Contents

Connections

Back to Table of Contents